2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bagby, S. P. Search for Related Content PubMed PubMed Citation Articles by Bagby, S. P.

Obesity-Initiated Metabolic Syndrome and the Kidney: A Recipe for Chronic Kidney Disease?

Division of Nephrology & Hypertension, Department of Medicine; OHSU Heart Research Center; Department of Physiology & Pharmacology; Oregon Health & Science University, Portland, Oregon

Correspondence to Dr. Susan P. Bagby, Departments of Medicine and Physiology/Pharmacology, Division of Nephrology & Hypertension, Oregon Health & Sciences University, 3314 SW US Veterans Hospital Road (PP262), Portland, OE 97239-2940. Phone: 503-494-8490; Fax: 503-494-5330; E-mail: bagbys{at}ohsu.edu

	Introduction

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 
Metabolic syndrome, originally described in 1988 as "syndrome X" by Reaven et al. (1), has evolved in our collective thinking from a vague association of common chronic disease states to a formally defined cluster of clinical traits with adverse impact on cardiovascular risk (2). The cause is incompletely understood but represents a complex interaction among genetic, environmental, and metabolic factors, clearly including diet (3,4) and level of physical activity (4,5). These abnormalities are mediated by—and interconnected by—complex pathways that affect energy homeostasis at cellular, organ, and whole-body levels. This review focuses on obesity-initiated metabolic syndrome, first to provide a pathogenetic overview of extrarenal metabolic derangements; second to consider predisposing conditions shaped by genetic or environmental factors, including growth constraints in utero; and finally to consider the impact of metabolic syndrome on the kidney in its prediabetic phase. The pathogenesis of hypertension in the context of metabolic syndrome is considered separately in this series. Similarly, central nervous system pathways that contribute to disordered energy homeostasis is addressed in detail by others. The mechanisms of irreversible renal injury from hypertension and overt diabetes are well documented and are beyond the scope of this review; nonetheless, they loom large in the long-term renal future of the patient with metabolic syndrome. The current worldwide epidemic of obesity-initiated metabolic syndrome, with its potential for renal damage, mandates our commitment to early renal protection in the obese and to vigorous prevention of obesity in both pediatric and adult populations.

	Metabolic Syndrome Defined: A Work in Progress

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 
The Adult Treatment Panel III (ATPIII) of the National Cholesterol Education Program (NCEP) (2) defines metabolic syndrome clinically as any three of the following five traits (Table 1): abdominal obesity, impaired fasting glucose (reflecting insulin resistance), hypertension, hypertriglyceridemia, and low HDL cholesterol. In addition, the NCEP ATPIII recognizes prothrombotic and proinflammatory states as characteristic of metabolic syndrome (2). Importantly, as subsequent paragraphs detail, these simple clinical criteria for diagnosis belie the emerging complexity of the underlying metabolic derangements (6). Thus, insulin resistance is viewed as the essential common denominator of metabolic syndrome, regardless of cause. Abdominal obesity, now identified solely by waist circumference criteria (Table 1), is the single most common cause of insulin resistance, and key mechanisms that mediate this pathway are becoming clear (6). Hypertension [defined in this high-risk context as 130/85 (2)] and the typical pattern of atherogenic dyslipidemia—hypertriglyceridemia, low HDL cholesterol, and increase in small dense LDL particles (2)—are also likely downstream consequences of insulin resistance with identifiable contributions from specific organs. Clinical criteria also do not emphasize the role of disordered skeletal muscle metabolism in this syndrome or highlight for the clinician the therapeutic power of regular exercise to offset insulin resistance. Finally, concepts now evolving from research advances suggest that the current clinical definition identifies individuals at a relatively advanced stage, well beyond onset of irreversible organ/tissue injury. Consequently, one immediate research challenge is to define, in the temporal evolution of metabolic syndrome, where interventions can both reverse metabolic derangements and prevent the tissue damage that conveys long-term risk.

	Prevalence and Cardiovascular Risks of Metabolic Syndrome

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

The 2002 NCEP ATPIII panel rated metabolic syndrome equivalent to cigarette smoking in magnitude of risk for premature coronary heart disease (2). In epidemiologic studies, metabolic syndrome increases risk of developing overt diabetes (16), cardiovascular disease (17,18), and cardiovascular mortality (17). In a prospective Finnish cohort, both NCEP ATPIII and World Health Organization criteria for defining metabolic syndrome predicted a five- to ninefold increase in risk of new diabetes over 4 yr (16). Lakka et al. (17), in a cohort of 1209 disease-free Finnish men who were aged 42 to 60 yr and followed for >11 yr, found that the presence of metabolic syndrome conferred a three- to fourfold increased risk for death from coronary heart disease. Using NHANES III data, Ninomiya et al. (7) described an approximately twofold increase in myocardial infarction and stroke risk in the presence of metabolic syndrome.

	Pathogenesis of Obesity-Initiated Metabolic Syndrome

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 
The NCEP panel identifies the root causes of metabolic syndrome as overweight/obesity, physical inactivity, and genetic factors (2). Unraveling underlying mechanisms has been complicated by the unique multiorgan complexity of this trait cluster. Fundamentally, the metabolic syndrome reflects disordered energy homeostasis. Just as evolution prepared us well for surviving hypotension but poorly for combating hypertension, it has apparently equipped us for surviving the fast but not the feast. Unger (19,20) described metabolic syndrome as "a failure of the system of intracellular lipid homeostasis which prevents lipotoxicity in organs of overnourished individuals," a system that normally acts "by confining the lipid overload to cells specifically designed to store large quantities of surplus calories, the white adipocytes." Central to the breakdown of this system are (1) exogenous fuel overload, (2) ectopic accumulation of lipid in nonadipose cells (21), and (3) insulin resistance (3,16).

To summarize concepts to be detailed below, the evolution of metabolic syndrome seems to proceed not as a linear sequence of events but along a matrix of interconnected pathways that mediate interactions among multiple organs and also link these organs as a functional unit to regulate total-body energy homeostasis (Figure 1). Each organ/cell type is typically both a target and an effector within this matrix. Furthermore, disturbance within this matrix of pathways can be initiated by stimuli acting at any one of multiple sites in the matrix (e.g., in adipocytes, in hepatocytes, in skeletal myocytes), each independently capable of disturbing whole-body fuel homeostasis. However, initiation of metabolic syndrome by obesity, in keeping with the now-recognized role of adipose tissue as an endocrine organ, is characterized by powerful systemic stimuli that together impair energy homeostasis in multiple organs simultaneously, leaving no room for protective compensation. This multiplicity of pathways and targets likely explains the efficacy of obesity as the major generator of metabolic syndrome.

View larger version (40K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 1. Pathogenesis of obesity-initiated metabolic syndrome. Increased abdominal fat mass yields high circulating free fatty acids (FFA), which drives increased cellular FFA uptake. Reduced release of adiponectin from expanding abdominal white adipose tissue (WAT) reduces mitochondrial FA uptake/oxidation in multiple tissues. Despite increased release of leptin from WAT, which normally also enhances FA oxidation, tissue resistance to leptin further promotes cytosolic FA build-up. As a result, excess intracellular FA and its metabolites (fatty acyl CoA, diacylglyceride) accumulate, causing insulin resistance (see pathway, Figure 2). Organ-specific consequences include increased hepatic gluconeogenesis and reduced skeletal muscle glucose uptake; the latter raises plasma glucose content and stimulates pancreatic insulin release, and hyperinsulinemia ensues. The newly available glucose plus high insulin now comes back full circle to stimulate further WAT lipogenesis. Increasing fat cell size induces release of chemotactic molecules (e.g., monocyte chemoattractant protein-1) with macrophage infiltration plus TNF- and IL-6 generation. These cytokines generate an inflammatory reaction and enhance adipocyte insulin resistance in WAT.

View larger version (38K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 2. Intracellular pathways of insulin resistance. Accumulation of FA and its metabolites (fatty acyl CoA and diacylglycerol) induce protein kinase C isoforms, leading to serine/threonine phosphorylation of insulin receptor substrate-1 (IRS-1) on serine 302. This renders the IRS-1 resistant to tyrosine phosphorylation by the activated insulin receptor. As a result, downstream effects of insulin receptor activation—Akt activation and translocation of the glucose transporter Glut 4 to the plasma membrane—is reduced. Glucose uptake is thereby diminished, secondarily decreasing both glucose-derived glycogen synthesis and glucose-dependent lipogenesis. Activation of the JNK pathway by elevated cytoplasmic FA may provide an additional pathway for induction of insulin resistance. Adapted from reference 52.

	Generation of Obesity-Associated Metabolic Syndrome: Reversible Derangements of the Metabolic Matrix

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

Role of Abdominal Obesity
Most studies support the view that the metabolic syndrome that now confronts U.S. physicians in epidemic proportions is largely initiated by abdominal obesity. The four most crucial elements that link abdominal obesity to other features of the metabolic syndrome seem to be elevated FFA, reduction in circulating insulin-sensitizing adiponectin, peripheral-tissue resistance to the insulin-sensitizing actions of leptin, and enhanced macrophage infiltration in fat tissue with release of proinflammatory cytokines (Figure 1). Abdominal fat is unique in its metabolic features as compared with peripheral fat depots, exhibiting larger adipocytes that contain more triglyceride (TG) and exhibit greater insulin resistance than smaller adipocytes. Adipocyte resistance to the lipogenic effect of insulin yields higher basal rates of lipolysis with increased release of FFA into the portal venous system. This direct access to the liver (see below) may also contribute to the unique impact of visceral fat on energy homeostasis. Abdominal fat may also secrete less leptin than subcutaneous fat. Thus Cnop et al. (28), comparing lean-insulin resistant, lean insulin-sensitive, and obese insulin-resistant adults, found that leptin levels correlated with increasing subcutaneous—but not visceral—fat mass, proposing yet another metabolic distinction between these two compartments. Abdominal fat mass expansion is also coupled with reciprocally reduced release of adiponectin, a multifunctional collagen-like molecule with potent capacity to stimulate fuel oxidation in peripheral tissues (25). Abdominal fat additionally expresses higher levels of renin-angiotensin system components: increased angiotensinogen and increased angiotensin II (Ang II) AT1 receptors (38). Finally, epidemiologic studies confirm the unique significance of abdominal fat mass in predicting microalbuminuria, diabetes, and overall cardiovascular risk (39). It was this compelling evidence for a unique role of central or visceral obesity—in contradistinction to subcutaneous obesity—that prompted the NCEP ATPIII decision to specify abdominal obesity in the clinical definition of metabolic syndrome.

These phenomena originating in abdominal adipose tissue generate the clinical picture that we recognize as metabolic syndrome. The roles of FFA excess and adiponectin deficiency are reviewed below in the context of their actions in individual organs; the role of leptin is addressed subsequently to compare and integrate prevailing views of how insulin resistance evolves.

	Liver

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 
Under conditions of normal energy homeostasis, the liver serves as a short-term energy reservoir, taking up absorbed dietary glucose and FFA, synthesizing/storing glycogen, synthesizing/storing TG, and packaging TG into VLDL. During fasting, the liver must sustain a continuous supply of plasma glucose, acutely by glycogenolysis and later in the fasting period by gluconeogenesis. Secreted VLDL provides ongoing TG and ultimately FA fuel to skeletal muscle, heart, and other peripheral tissues via lipoprotein lipase activity in the vascular space.

Effect of Excess FFA on Liver
Intracellular FFA content is a function of substrate delivery from the plasma and FFA utilization (efflux into mitochondria for oxidation or cytosolic synthesis of intracellular lipids). With abdominal obesity, the increased FFA released into the portal vein from excess visceral fat lipolysis have direct access to the liver. Because cellular FA uptake is substrate dependent, increased hepatocyte FFA uptake ensues (23). Elevated cytoplasmic FA content leads to hepatic insulin resistance. This process involves competition of FA and glucose for access to mitochondrial oxidative metabolism. The molecular mechanism was recently described by Shulman et al. (40,41) (Figure 2), wherein elevated intracellular fatty acyl CoA activates protein kinase C (PKC), causing phosphorylation of serine-302 of insulin receptor substrate-1 (IRS-1). This renders IRS-1 unavailable for tyrosine phosphorylation by the activated insulin receptor and reduces all downstream actions of insulin. As a result, the fasting state is simulated and hepatocyte enzymatic machinery is shifted to favor enhanced hepatic gluconeogenesis at the expense of glycogen synthesis. The consequent increase in liver-derived glucose in plasma leads to hyperinsulinemia, a hallmark of metabolic syndrome in its earliest stage and a marker of insulin resistance.

The capacity of the insulin-resistant liver to impair secondarily systemic energy homeostasis is illustrated by transgenic studies introducing an insulin-resistant form of the rate-limiting enzyme of liver gluconeogenesis: phosphoenolpyruvate carboxykinase (42). Creating isolated hepatic insulin resistance led to systemic hyperglycemia, hyperinsulinemia, and a moderate increase in fat mass (42). The last reflects WAT utilization of surplus circulating glucose for insulin-induced lipogenesis. In effect, this represents a redistribution of fuel away from the liver to adipose fat stores. These findings emphasize the potential for activating the abnormal metabolic matrix simply by inducing hepatic insulin resistance and also illustrate the dual role of the liver as target and effector in metabolic syndrome derangements. In dogs that were fed an isocaloric moderate-fat diet, striking visceral obesity was associated with marked reduction in the ability of insulin to suppress hepatic gluconeogenesis, even before any reduction in insulin-stimulated glucose uptake appeared; investigators concluded that hepatic insulin resistance plays a dominant role in the pathophysiologic cascade initiated by abdominal obesity (43).

FFA overload also provides substrate for increased hepatic TG synthesis and for TG-rich VLDL assembly and secretion. Although details are beyond the scope of this review, the peripheral metabolism of these VLDL generate a small, dense form of highly atherogenic LDL [reviewed by Avramoglu et al. (44)] along with an increase in plasma TG. In addition, increased hepatic lipase activity in the insulin-resistant state reduces levels of protective HDL-2 cholesterol (45), which is essential to the transport of cholesterol from tissues back to the liver. Thus, hepatic insulin resistance, high plasma TG, and low plasma HDL are pathogenetically linked manifestations of altered lipid regulation in metabolic syndrome.

Effect of Adiponectin Deficiency on Liver
In addition to the effects of elevated FFA load, the energy-related functions of the liver are profoundly affected by the reduced circulating levels of the adipokine adiponectin. The actions of this multifunctional protein are organ specific and uniformly insulin sensitizing. Adiponectin normally promotes insulin sensitivity in liver in part by enhancing FA oxidation (46); this reduces accumulation of cytoplasmic FA, thereby reducing intracellular FA levels and enhancing insulin action via IRS-1 availability to the insulin receptor. Second, like insulin, adiponectin normally suppresses hepatic gluconeogenic enzymes and induces glycogenetic enzymes. Increase in 5'-AMP-activated kinase mediates these effects of adiponectin (46,47). Conversely, deficiency of adiponectin in states of abdominal obesity directly contributes to insulin resistance by further enhancing accumulation of intracellular FA and FA metabolites and by stimulating hepatic glucose output. The impact of insulin-sensitizing adipokines is apparent from transgenic mouse models that completely lack fat (and thus both adiponectin and leptin) (48). Animals are insulin resistant; the provision of physiologic levels of both adiponectin and leptin fully restores normal energy homeostasis, whereas either alone is only partially effective (48). These studies underscore the regulatory role of fat-derived adipokines and lend logic to the seeming paradox that either too little or too much adipose tissue can lead to insulin resistance (21).

	Skeletal Muscle

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 
Increased circulating FFA also have an impact on skeletal muscle energy homeostasis. Skeletal muscle is normally a major site of glucose and FA uptake, accounting for the bulk of total-body glucose utilization and deriving 60% of resting energy from FA. As in the hepatocyte, increase in intramyocellular FA in skeletal muscle has been shown to impair insulin receptor signaling by PKC-dependent serine phosphorylation of IRS-1; this leads to reduced IRS-1 availability for tyrosine phosphorylation, reducing Glut 4 translocation to the myocyte plasma membrane with consequent reduction in glucose uptake (6). Secondarily, glucose-driven lipogenesis and glycogen synthesis in skeletal myocytes are also reduced. Accordingly, elevated circulating FFA contribute to insulin resistance in both liver and skeletal muscle.

As in the hepatocyte, reduced adiponectin secretion secondary to increased visceral fat mass augments insulin resistance in skeletal muscle, also in part via reducing FA oxidation rate, further increasing intramyocellular FA content and impairing insulin action (48). Using magnetic resonance spectroscopy in insulin-resistant offspring of patients with type 2 diabetes, Petersen et al. (49) found evidence of a 30% reduction in mitochondrial oxidative phosphorylation together with impaired muscle FA oxidation and an 80% increase in intramyocellular lipid content. Overt diabetes has also been associated with impaired muscle oxidative capacity (50,51). Finally, the insulin resistance of aging is associated with impaired mitochondrial FA oxidative capacity in skeletal muscle (52).

Impaired energy production is a particularly important consequence of insulin resistance in skeletal muscle. Diabetic and prediabetic patients have impaired maximal exercise capacity, reduced maximal oxygen consumption, and slower oxygen uptake at initiation of low-level exercise, potentially contributing to the fatigue and reduced physical activity typical of obesity/insulin resistance (53). Exercise stimulates skeletal muscle oxidative enzymes and activates mitochondrial biogenesis (54). Inactivity would be predicted to reduce basal metabolic rate both by reducing muscle mass and by augmenting defective muscle energy production. The practical physical consequences of these skeletal muscle metabolic abnormalities have not yet been widely studied in metabolic syndrome but are likely to reinforce the vicious cycle of ongoing weight gain and sedentary lifestyle.

	Pancreas

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 
The pancreas is the ultimate arbiter of insulin availability, determining the point at which overt diabetes will occur. Early in the course of metabolic syndrome, hepatic gluconeogenesis stimulates the pancreas to hypersecrete insulin, yielding normoglycemic hyperinsulinemia. Increased FFA uptake by pancreatic cells also increases glucose-induced insulin secretion and modifies expression of peroxisome proliferator–activated receptor- (PPAR-), glucokinase, and Glut 2 transporter (23). In the spontaneously obese captive rhesus monkey, hyperinsulinemia is sustained and progressively increases, eventually falling as overt hyperglycemia appears (55). Once hyperglycemia ensues, insulin-secreting cells become targets of glucotoxicity: reduction in insulin-stimulated insulin secretion, late increase in mitochondrial free-radical production, and lipid overload–induced apoptosis (lipotoxicity; see also below) with progressive loss of cell mass (56–58). Adverse effects of hyperinsulinemia per se on organ structure and function in the prehyperglycemic phase of metabolic syndrome are not well defined but are relevant to establishing optimum timing of intervention. It is worthy of emphasis that lifestyle interventions that reduce hyperglycemia can markedly decrease progression to overt diabetes (59).

	Vascular Endothelium

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 
Available evidence indicates that the insulin-receptor signaling pathway mediating glucose uptake in vascular endothelium requires stimulation of endothelial nitric oxide (NO) synthase and NO production (60), a potent vasodilatory and antithrombotic stimulus. Comparable endothelial responses—enhanced NO production with vasodilation—are induced by adiponectin (61). These actions mediate a hemodynamic component of energy distribution, enhancing tissue blood flow to optimize nutrient delivery. When insulin resistance ensues, insulin-induced NO production is concomitantly impaired, representing one of several mechanisms linking abdominal obesity/insulin resistance and hypertension. Implications of endothelial dysfunction for hypertension in metabolic syndrome are addressed in detail by Dr. Sowers elsewhere in this issue.

	Role of Leptin Resistance in Peripheral Organs

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 
In addition to FFA excess and adiponectin deficiency, functional leptin deficiency in peripheral tissues is believed to play a significant role in the evolution of obesity-initiated insulin resistance. Leptin is secreted in proportion to body fat mass and, under normal circumstances, signals via central nervous system receptors to attenuate appetite and to enhance sympathetic outflow, the latter stimulating energy utilization and thermogenesis. Increase in fat-derived plasma leptin seen with abdominal obesity states is paradoxically coupled with poorly understood leptin resistance to central appetite-suppressing and to peripheral insulin-sensitizing effects of leptin (see below), thus a functional leptin deficiency. Central pathways of adipocytokines are addressed separately in this series. Unger and colleagues (62) proposed, on the basis of compelling experimental evidence, that peripheral-tissue leptin resistance is a crucial factor leading to insulin resistance in metabolic syndrome (19). They contended that leptin’s major role in normal energy homeostasis is not prevention of obesity, as originally conceived, but rather protection of nonadipocytes against the cytotoxicity of intracellular lipid overload during periods of nutrient excess (21,24). Leptin potently activates cellular fuel consumption by stimulating FA oxidation, reducing lipogenesis, enhancing glucose entry and metabolism, and dramatically shrinking fat stores in adipose tissue (63) as well as in muscle and liver cells (24). Accumulation of cytoplasmic FA thus could reflect functional leptin deficiency acting via impaired mitochondrial oxidative capacity and concomitantly enhanced lipogenesis. The ensuing insulin resistance could be viewed as a compensatory cytoprotective response to prevent further accumulation of intracellular lipid, i.e., reduced glucose entry attenuates glucose-derived lipogenesis (21). The mechanisms of peripheral resistance to the fuel-burning actions of leptin are not yet known. In reality, excess FFA in the circulation, leptin resistance, and adiponectin deficiency are likely acting in concert to generate intracellular FA excess, although their precise sequence and relative importance remain to be determined. The biochemical pathways involved in these intracellular processes have been reviewed in detail by Unger (19,21), Petersen and Shulman (64), and Shulman (6). The crucial participation of PPAR-, -, and - in mediating tissue-specific actions of adiponectin and leptin—and their alterations in metabolic syndrome—are addressed separately in this series.

	Meanwhile, Back to Fat

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 
Although excess abdominal fat serves to initiate dysfunctional energy homeostasis in multiple other organs, it eventually becomes also a target tissue. It is first a target of excess glucose in the vascular space. Increased glucose availability from liver-based gluconeogenesis and from muscle-based reduction in glucose uptake, together with pancreas-dependent hyperinsulinemia, promote lipogenesis in WAT (42) (Figure 1). This poses the disturbing possibility that abdominal obesity creates a self-perpetuating cycle.

Excess cortisol activity is known to shift fat from peripheral (gluteal and subcutaneous) to central visceral depots and to mimic many aspects of metabolic syndrome. It thus is not surprising that glucocorticoid excess has been suspected in the cause of metabolic syndrome. Recently, increased activity (65) and a twofold increased expression of 11 hydroxy steroid dehydrogenase 1 (11HSD1) in adipose tissue of nondiabetic centrally obese women (66) were reported. This enzyme acts predominantly to convert inactive cortisone to the active cortisol form, thus generating glucocorticoid at a tissue level. Expression levels of 11HSD1 were directly proportional to waist circumference and insulin resistance (66). Supporting the relevance of locally generated glucocorticoid in WAT, transgenic mice overexpressing 11HSD1 in adipocytes faithfully reproduced the metabolic syndrome (67,68), whereas deficient mice were metabolically resistant to high-fat feeding (69). Once again, a change confined to fat tissue induces systemic metabolic dysregulation.

Expanding WAT also becomes the primary target of an inflammatory process. Recent studies in mice and human adipose tissue elegantly documented this process and implicated the role of macrophage infiltration and macrophage-derived inflammatory mediators in obesity and metabolic syndrome (30,31). Weisberg et al. (31) demonstrated that increasing body mass and increasing fat-cell volume (i.e., fat content) each correlates linearly with bone marrow–derived macrophage infiltration in WAT and linearly with increased expression of macrophage-linked proinflammatory genes (Figure 3). Xu et al. (30) similarly found that upregulated genes in WAT of obese mouse models were primarily inflammatory genes linked to macrophage infiltration/activation; furthermore, in diet-induced obesity, this inflammatory process within WAT preceded insulin resistance. TNF- and IL-6 have been shown to induce insulin resistance in vitro and to contribute to insulin resistance in mouse models of obesity (36,70). This in situ inflammatory reaction within WAT therefore may induce/augment insulin resistance in the adipocytes per se, coming full circle in generation of multiorgan energy dysregulation.

View larger version (63K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 3. Macrocyte infiltration in WAT correlates linearly with body mass index and adipocyte size/fat content (31). In human subcutaneous adipose tissues obtained from individuals with widely ranging body mass index (BMI), density of macrophage infiltration (measured by PCR quantification of CD68 mRNA, a specific macrophage marker) correlated linearly with BMI (a) and with average adipocyte cross-sectional area, an index of cell fat content (b). Squares and diamonds represent female and male subjects, respectively. (c and d) Representative photomicrographs of adipose tissue biopsies from obese (BMI 50.8 kg/m2; c) and lean (BMI 25.7 kg/m2; d) female subjects show the larger adipocyte area in obesity; arrows indicate F4/80+/bone marrow–derived macrophages. In studies in agouti (Ay) and obese (Lepob) mice and in humans, adipose tissue macrophages accounted for virtually all of adipose TNF-, inducible nitric oxide synthase, and IL-6 expression (31), cytokines implicated in locally enhancing insulin resistance in WAT (Reproduced by permission from Weisberg SP, et al., J Clin Invest 112: 1796-1808, 2003).

	Predisposition to Obesity-Initiated Metabolic Syndrome

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

	Lessons from Intrauterine Growth Restriction

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 
Asymmetric Intrauterine Growth Restriction Produces the "Thrifty Phenotype"
Epidemiologic studies over the past 15 yr have uncovered a consistent relationship between low birth weight and increased risk for developing adult metabolic syndrome (75), a phenomenon now known as developmental "programming." For example, in the Hertfordshire Study, prevalence of metabolic syndrome according to birth weight fell stepwise from 30% of subjects who were 5.5 lb to 6% of those who were 9.5 lb (76). A key feature that conveys risk in programming is not low birth weight per se but rather a form of asymmetric growth restriction wherein weight is disproportionately impaired relative to height, and sizes of kidney, liver, pancreas, and skeletal muscle are disproportionately reduced relative to heart and brain (77,78). When asymmetrically growth-restricted infants encounter nutrient abundance postnatally, there is spontaneous "compensatory" or "catch-up" growth such that body weight increase is accelerated and crosses percentiles during childhood (79,80). In a rat model of global maternal calorie restriction, offspring that were weaned to normal diets postnatally were permanently hyperphagic, hyperinsulinemic, and hyperleptinemic; exhibited catch-up growth; and developed increase in central fat mass and hypertension as adults; all features were exaggerated by a highly palatable "cafeteria" diet (81). Human epidemiologic studies based on large longitudinal databases from diverse countries now demonstrate that rapid compensatory growth in childhood is a significant enhancer of adult cardiovascular disease risk in offspring with intrauterine growth restriction (IUGR), specifically including central obesity (76,82,83), diabetes (84–86), hypertension (87,88), and coronary disease (79,80). Specific patterns of postnatal growth after IUGR influence the magnitude of risk for specific elements of the metabolic syndrome. Thus, in a South African cohort, low-birth-weight children who were exposed to nutrient abundance and catch-up growth exhibited increased propensity for fat more than lean mass deposition and increased risk of obesity and insulin resistance by age 7 as compared with those who did not undergo catch-up growth (89). In a Finnish cohort that contained extensive longitudinal growth data in childhood, the subset of individuals who subsequently developed hypertension as adults exhibited a distinct pattern of childhood growth: low birth weight followed by an exaggerated growth rate in weight greater than height to attain increased BMI levels by 12 yr (88) (Figure 4). When the population was subdivided, children who were destined to develop only hypertension exhibited exaggerated growth to attain average-for-age BMI by age 7, which remained constant thereafter; children who were destined to develop both hypertension and diabetes as adults exhibited a similar pattern between birth and age 7 but differed by continuing rapid growth between 7 and 15 yr of age to reach excess BMI (87). Thus, early growth restriction in an asymmetric pattern leads to "programmed" increase in appetite, excess food intake when available, exaggerated childhood "catch-up" growth with a propensity for accruing fat more than lean body mass, and preferential deposition of abdominal more than peripheral fat (89,90). Hales (91) termed this constellation of traits the "thrifty phenotype."

View larger version (25K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 4. Pattern of infant and childhood growth in children who developed hypertension as adults. Growth rates are expressed as SD units (z scores) from the overall population average (set at zero). The 1404 of 8760 children who subsequently required antihypertensive medications as adults exhibited low birth weight and low birth BMI but exaggerated growth in weight and BMI between 5 and 12 yr of age. (Reproduced by permission from Barker DJ, et al., J Hypertens 20: 1951-1956, 2002).

Studies in a Microswine Model of IUGR: Reduced Nephron Number, Intrarenal Ang II Excess, and Hypertension in Adult Offspring
Our investigative group has pursued the hypothesis that exaggerated postnatal increase in body mass in the face of developmentally fixed nephron deficit would favor nephron adaptations of hypertrophy and hyperfiltration and increase in glomerular capillary pressure independent of obesity. That is, two independent consequences of IUGR—nephron deficit and thrifty-phenotype traits—interact to create imbalance between metabolic/excretory load and renal excretory capacity (Figure 5). To test this, we developed a microswine model of IUGR using maternal protein restriction during the window of nephrogenesis (in swine, the last one third or gestation plus first 2 wk postnatally). Offspring of low-protein sows, as compared with control offspring, exhibit a typical asymmetric pattern of growth restriction, have evidence of 30% reduction in nephron number, undergo 100% catch-up growth of body and organ sizes, and develop hypertension as young adults (6 mo) (104). In adults, renal weight and function are normal, but glomerular volume is increased, compatible with nephron hypertrophy and hyperfiltration. Woods et al. (94) reported similar findings in rat offspring of protein-restricted dams. We further proposed that this mismatch of excretory load to excretory capacity would induce compensatory nephron hyperfiltration via activation of the renin/Ang II system. In examining plasma components of renin/Ang II activity (105), we find no differences among low-protein versus normal-protein offspring for Ang II, plasma renin activity, or renin substrate concentration. In contrast, intrarenal Ang II levels are elevated in hypertensive adult low-protein offspring (106). This pattern of normal renin/Ang II status in plasma but activated status intrarenally is reminiscent of that observed in the diabetic kidney (107). In our 6-mo-old young-adult offspring of maternal protein restriction, glomerulomegaly and intrarenal Ang II excess are present in the absence of proteinuria (106). To distinguish between body mass excess and developmental programming of the renin/Ang II system as causes of these changes, we are currently examining whether prevention of catch-up growth by early postnatal caloric restriction modifies the renal adaptations, intrarenal Ang II, and hypertension.

View larger version (43K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 5. Proposed interaction between thrifty phenotype behaviors and fixed reduction in nephron number after intrauterine growth restriction. Fetal nutrient deprivation of any cause encompassing the last half of pregnancy typically impairs renal development and reduces nephron number. No new nephrons form after birth in humans. Nutrient deprivation also "programs" the fetus to utilize energy more efficiently, optimizing survival. Postnatally, the offspring exhibit hyperphagia on the basis of ad libitum food intake, increased efficiency in utilization of calories, and metabolic changes that reduce maximum capacity for energy consumption (reduced muscle mass, smaller mitochondria). If food is available in the environment, then hyperphagia drives caloric intake to yield rapid compensatory growth in weight more than height, crossing centiles to achieve typically normal BMI. Even in the absence of overt obesity, this now-normal body mass is relatively excessive for the fixed reduction in nephron number. In a microswine model, catch-up growth is associated with intrarenal angiotensin II excess and hypertension in young adults. This may be analogous to the increased risk of hypertension and proteinuria when obesity precedes unilateral nephrectomy.

Programming Can Occur after Birth and Can Be Transmitted to Offspring
Nutritional programming of postnatal homeostasis during periods of developmental plasticity is not confined to the fetal period. Srinivasan et al. (110) showed metabolic programming in neonatal rats in response to high-carbohydrate versus normal high-fat milk formula during postnatal days 4 to 24. Adaptations in the high-carbohydrate pups included life-long hyperinsulinemia, increased number and size of pancreatic islets, and adult-onset obesity (110). It is especially noteworthy that the high-carbohydrate-fed female rats transmit this phenotype to their progeny (110), much as diabetic mothers transmit risk of diabetes to offspring via the intrauterine environment (108). Similarly, female IUGR offspring deliver low birth weight babies (73), another example of a transgenerational effect that may confound interpretation of studies in which transmission of maternal traits has been viewed as "genetic." This transgenerational reach of fetal programming (111,112) is not currently understood but potentially relates to factors such as developmentally impaired vascularization of the uterus and/or nutritional effects on a female infant’s developing ova.

	Genetic Predisposition to Metabolic Syndrome

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 
In addition to age, demographic factors, and developmental programming, germline transmission of predisposing factors clearly contributes to risk of metabolic syndrome. Furthermore, the array of molecules and pathways involved in its generation—representing the entire molecular infrastructure of energy metabolism and its regulation—underscore the many candidate sites. A detailed listing is beyond the scope of this review. Instead, selective examples highlight major pathophysiologic pathways. Virtually all genetic mechanisms described involve interaction with environmental factors (e.g., nutrient abundance, sedentary lifestyle) to create metabolic disease. In the Quebec Family Study, Tremblay et al. (113) described in older children and adolescents a glucocorticoid receptor polymorphism that predicted twofold increase in visceral adiposity in girls >12 yr (a similar trend in boys was NS). Similarly, abdominal visceral fat was linked with an RFLP at the glucocorticoid receptor locus (114). As predicted from its antidiabetic efficacy, human adiponectin mutants have also been associated with diabetes: Waki et al. (115) reported two mutants that failed to form the high-molecular-weight multimers required for adiponectin secretion from the adipocyte. Genetic predisposition to insulin resistance has also received attention in relation to PPAR-2. A Gly483Ser missense mutation in the PPAR- coactivator 1 gene was associated with reduced lipid oxidation, larger abdominal adipocyte size, and higher plasma FFA concentration in Pima Indians and in Danish populations (116). Muller et al. (117) found that a functional variant in the PPAR-2 promoter with reduced transcriptional activity also predicted obesity and insulin resistance in the high-risk Pima Indian population. A Pro12Ala polymorphism in PPAR-2 also predicted insulin resistance in Pima Indians and in other populations (117). Of special note, the effects of the Pro12Ala polymorphism on lipid metabolism was apparent only in individuals with low birth weight (118), a fascinating example of an interaction between a classic genetic factor and early environmental programming.

	Renal Injury in Obesity-Initiated Metabolic Syndrome: Epidemiologic Studies

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 
Evidence linking metabolic syndrome and renal disease has only recently emerged. In the Modification of Diet in Renal Disease study, a low HDL cholesterol independently predicted renal disease progression in 840 patients (119). In the Atherosclerosis Risk in Communities study of >12,000 subjects, Muntner et al. (120) observed that, in individuals who had baseline creatinine <2.0 and were followed for 2.9 yr, high TG increased (adjusted relative risk, 1.65) whereas high HDL cholesterol reduced (adjusted relative risk, 0.47) the probability of developing renal dysfunction.

However, these observations did not directly address the impact of the full metabolic syndrome as currently defined. To that end, Chen et al. (121) recently compiled data from the NHANES III survey to examine the association between metabolic syndrome and the respective risks for chronic kidney disease (CKD) and microalbuminuria in U.S. adults. CKD was defined as GFR (Modification of Diet in Renal Disease formula) of <60 ml/m per 1.73 m²; microalbuminuria as protein:creatinine ratio of 30 to 300 mg/g, and clinical proteinuria as ratio >300 mg/g. Not only was each element of the metabolic syndrome associated with increased prevalence of CKD and microalbuminuria, but also there was a graded relationship between the number of components present and the corresponding prevalence of CKD or microalbuminuria (P < 0.001 for each; Figure 6). Also using NHANES III data, Palaniappan et al. (122) found that the presence of metabolic syndrome was associated with an increased risk of microalbuminuria: odds ratio, 2.2 (1.4–3.3) in women and 4.1 (2.5–6.7) in men. Finally, Chen et al. (123) found that insulin resistance and hyperinsulinemia in individuals without diabetes strongly and positively predicted CKD and suggested that intervention to ameliorate insulin resistance could lower CKD risk. To date, however, there are no clinical trials addressing whether treating metabolic syndrome elements other than hypertension or diabetes will reduce risk of renal disease onset or progression; neither are there trials defining optimum target levels of treated components in these settings.

View larger version (37K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 6. Risk for chronic kidney disease (CKD; top) and microalbuminuria (bottom) according to number of metabolic syndrome elements. A significant graded relationship was apparent between number of components and corresponding prevalence of CKD or microalbuminuria (P < 0.001 for each comparison). (Adapted with permission from Chen J, et al., Ann Intern Med 140: 167–174, 2004).

	Potential Mechanisms of Early Renal Injury

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

Mechanisms of Renal Injury
Although hypertensive and diabetic modes of injury are well described and beyond our scope, we can speculate on mechanisms of early renal damage in obesity-initiated metabolic syndrome. Several possibilities—acting singly or in combination—deserve consideration: (1) adverse effects of adaptations to increase body mass/excretory load, (2) adverse effects of adaptations to obesity-induced sodium retention (127), (3) direct or indirect effects of hyperinsulinemia/insulin resistance, and (4) renal lipotoxicity [see recent reviews by Hall et al. (127), Adelman (128), and Praga (129)].

	Excess Excretory Load

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 
Obesity is associated with an excess excretory load on the basis of increased body mass and the increased energy intake and tissue turnover required to maintain it. Fat-free body mass (130) is also increased in obesity; in keeping with functional overload, the organomegaly of obesity includes both the heart and the kidneys (131). Chagnac et al. (132) confirmed renal hyperperfusion and hyperfiltration in severe obesity, averaging 51 and 31% increases, respectively. The reduced renal resistance with increased filtration fraction was compatible with net afferent dilation and glomerular capillary hypertension (132), the classic recipe for eventual glomerulosclerotic damage. Furthermore, in keeping with glomerular hypertension, the first clinical evidence of renal disease in obesity is proteinuria (see below); weight loss can strikingly reduce proteinuria as a result of obesity per se or of other underlying causes (133,134). In effect, obesity induces—even at normal nephron capacity—the single-nephron adaptations typical of the reduced nephron number accompanying CKD. Nephron overwork and risk of intraglomerular hypertension in obesity would be exaggerated if nephron number is already low, as would be predicted in offspring with IUGR (103) or after uninephrectomy (135). Increased glomerular risk as a result of transmission of systemic hypertension is also likely to apply. If chronic intrarenal Ang II excess proves typical of load adaptation, then Ang II could further enhance renal risk by proinflammatory mechanisms and by promoting proteinuria-related renal damage. Of interest in relation to load-induced nephron adaptation, Schwimmer et al. (136) reported focal segmental glomerulosclerosis (FSGS) and glomerulomegaly in three nonobese patients with markedly increased muscle mass, as evidenced by BMI of 30 to 32, body fat of only 13 to 17%, and nonnephrotic proteinuria 1 g/d. GFR of 113 to 208 suggested hyperfiltration; FSGS affected a minority of glomeruli, and foot process effacement was minimal. Because insulin resistance/hyperinsulinemia would not be expected in this setting, the changes—albeit in only three patients—conceptually support the view that excess excretory load—whether derived from lean or fat tissue—is an important factor in inducing glomerulomegaly and glomerulonephropathy.

	Adverse Adaptations to Excess Renal Na Retention

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 
Hall et al. (127) proposed that, in response to the reduced Na excretion capacity acting at sites proximal to the macula densa in obesity (via Ang II and sympathetic activation), reduced NaCl delivery to the macula densa site induces afferent vasodilation and renin release to produce compensatory glomerular hyperfiltration, thereby restoring normal distal delivery. A similar scenario has been proposed by Thomson et al. (137) for hyperglycemia-induced increase in proximal tubular Na reabsorption in frank diabetes. As with hyperfiltration driven by excess excretory load, the ensuing intraglomerular hypertension and proteinuria represent the final common pathway leading to chronic glomerular and tubular injury.

	Adverse Renal Effects of Hyperinsulinemia/Insulin Resistance

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 
Recent evidence supports early development of pathophysiologic functional and structural changes. Thus, in the captive rhesus monkey with spontaneous obesity, glomerular hypertrophy appears in the prediabetic hyperinsulinemic phase despite no hyperglycemia, no hypertension, no renal dysfunction, and no increase in mesangial matrix deposition (124). However, these observations do not distinguish between effects of insulin resistance and hyperinsulinemia. Hall et al. (127) summarized evidence that high insulin per se has no adverse impact on BP in the normal or in the obese insulin-resistant dog. However, insulin—although a weak vasodilator—augments endothelial-dependent vasodilation; thus, hyperinsulinemia could contribute to preglomerular vasodilation and glomerular hypertension and require time to manifest damage. On the basis of in vitro observations, hyperinsulinemia could induce glomerular hypertrophy either directly (138) or by stimulating the IGF-1 receptor (138). IGF-1 actions (or actions of high insulin levels at the IGF-1 receptor) also include vasodilation (139) and may increase glomerular capillary permeability (140). Hyperinsulinemia could further interact with elevated intrarenal Ang II levels to augment Ang II contraction of glomerular mesangial cells (141). In addition, Abrass et al. (142) showed that high-dose insulin exerts direct pathologic effects on renal mesangial cells in culture, stimulating expression of inflammatory collagens typical of the diabetic phenotype. Importantly, the latter was not reversible on subsequent withdrawal of insulin (143,144), suggesting permanently altered gene expression after exposure to high insulin. Again in the rhesus monkey, hyperinsulinemia—with or without hyperglycemia but not hyperglycemia with low insulin—was associated with an altered ratio of insulin receptor splice variants in liver and skeletal muscle (145). Finally, although hyperinsulinemia may achieve normal insulin action in insulin-resistant organs, it could lead to excess insulin action/glucose uptake and promote lipogenesis/lipotoxicity in sites with persistent insulin sensitivity. The evidence that hyperinsulinemia—in conjunction with increased glucose availability—actively promotes adiposity in WAT via just such a mechanism has already been discussed (Figure 1). These considerations underscore the importance of learning more about the structural and functional effects on specific tissues during the hyperinsulinemic, prehyperglycemic phase of metabolic syndrome. Whether injury at this early stage reflects insulin resistance and/or hyperinsulinemia, therapeutic intervention in metabolic syndrome could ultimately prove to be necessary at a much earlier stage than currently considered.

	Renal Lipotoxicity?

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 
A well-documented form of multiorgan injury associated with progression of metabolic syndrome is lipotoxicity (21,23,24). This cytotoxic process, marking advanced stages of intracellular lipid overload, involves intracellular shunting of excess FA toward synthesis of lipid products that are capable of inducing cell damage: e.g., diacylglycerol, TG, and ceramide (Figure 2). Diacylglyeride enhances PKC activities; ceramide is a major candidate mediator of apoptosis (19). Evidence indicates that lipotoxicity affects liver (hepatic steatosis), skeletal muscle, cardiomyocytes, pancreatic cells, and potentially endothelial cells (24). This process not only impairs function in the individual cell but also reduces cell mass via apoptosis in multiple organs, each with important functional consequences. Lipotoxicity in proximal tubular cells—with its associated tubulointerstitial inflammation—is now a recognized consequence of heavy proteinuria as a result of accumulation of excess albumin-bound FFA (146,147). However, no studies have systematically addressed whether FFA lipotoxicity afflicts renal cell types in obesity-initiated metabolic syndrome, particularly in the absence of (or independent of) proteinuria. The mesangial cell would seem at particular risk for exposure to high circulating FFA bound to albumin in the face of intraglomerular hypertension.

In the presence of proteinuria—whether as a result of obesity per se or of other nephropathies—elevated plasma FFA in metabolic syndrome would be expected to enhance the number of FFA moieties bound to albumin and thus to enhance the FFA available for proximal uptake. Therapeutic lowering of FFA could potentially ameliorate proteinuria-associated proximal tubular lipotoxicity and tubulointerstitial nephritis. Oxidative stress is another potential mechanism of FFA toxicity: reactive oxygen scavengers block FFA-induced apoptosis in vitro (19). FFA both upregulate inducible NO synthase and generate reactive intermediates as byproducts of oxidative phosphorylation. High FFA per se during early metabolic syndrome, independent of intracellular TG accumulation, may be an important co-factor in epidemiologic linkage of abdominal obesity and microalbuminuria (148).

Obesity-Associated Glomerulonephropathy
Weisinger et al. (149) first reported massive proteinuria associated with obesity in 1974. Subsequent reports have consistently confirmed the presence of proteinuria and glomerulomegaly in obesity, often with FSGS (131,134,150,151). Thus, Verani et al. (131) reported an autopsy study of 22 kidneys from obese subjects: glomerulomegaly was a consistent feature; FSGS was present in seven with no predilection for juxtamedullary sites. In 15 obese individuals with FSGS, Praga et al. (151) further emphasized absence of clinical nephrosis despite heavy proteinuria and a 46% rate of renal progression. In 2001, D’Agati and colleagues (150) reported a striking 10-fold increase in incidence of a similar histopathologic entity that they termed obesity-related glomerulopathy. Seventy-one renal biopsies from obese patients (BMI >30 kg/m²) were compiled from 6818 consecutive biopsies over 10 yr. All were associated with glomerulomegaly, and all exhibited proteinuria (48% nephrotic range). Two histologic types were identified: FSGS and glomerulomegaly only. The obese FSGS group (n = 57) differed from classic idiopathic FSGS (n = 50 in a comparison group) via concomitant presence of glomerulomegaly, less clinical nephrosis, less severe proteinuria, less podocyte injury, less cholesterol elevation, and more indolent progression (150). Also of note, these FSGS lesions occurred across the spectrum of obesity, not just in class III (morbid) obesity. Of equal interest were the 14 proteinuric obese patients who exhibited only glomerulomegaly on biopsy (150), suggesting the possibility that glomerular hypertrophy alone in hyperinsulinemic obesity may induce or be associated with macroproteinuria (150). Although sampling error could not be excluded, the previous autopsy report of Verani et al. (131) supported the view that apparent absence of FSGS did not reflect a predominantly juxtamedullary localization. Whether glomerulomegaly is a cause or simply an associated feature of proteinuria in obesity-related glomerulomegaly is unknown. Similarly, whether glomerulomegaly is a precursor of the obesity-related FSGS lesion remains to be demonstrated. These findings again raise the issue of where in the course of obesity/metabolic syndrome renal injury is initiated and when intervention should be considered to prevent irreversible disease. [Excellent recent reviews of obesity and renal disease are available by Adelman (128), Hall et al. (127), and Praga (129).]

Our growing understanding of the pathogenesis of metabolic syndrome provides the rationale for management strategies to achieving long-term renal and cardiovascular protection. As clearly demonstrated by primate studies (126,152,153), obesity-associated metabolic syndrome and its entire cascade of consequences can be resolved by weight loss and prevented by caloric restriction. Intensive programs of exercise and weight loss in individuals with metabolic syndrome also achieve dramatic improvement (59,154). In the Diabetes Prevention Program Research study (59), the lifestyle intervention achieved a 58% reduction in the incidence of diabetes in individuals who already exhibited hyperglycemia. As difficult as these changes may be, there is no intervention more powerful. There is also no motivator more effective than a knowledgeable and concerned physician who is willing to convey personally the importance and the feasibility of lifestyle change. Growing understanding of the direct skeletal muscle benefits of regular exercise to offset insulin resistance, even in the absence of weight loss, makes this a mandatory recommendation well worthy of the education and counseling time invested.

Pharmacologic interventions with well-established benefit include angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, which increase insulin sensitivity (155) and ameliorate microalbuminuria in addition to their well-documented cardiovascular and renal protections (156); their use with BP >130/80 complies with the BP goal for metabolic syndrome (2). Statins are currently under study in prospective trials to assess their contribution to renal protection and are clearly indicated in the presence of hypercholesterolemia. Evidence that statins have anti-inflammatory benefit independent of lipid lowering suggests that clinical trials of their use in normocholesterolemic metabolic syndrome will be forthcoming. Metformin has been shown to be effective in preventing development of diabetes in prediabetic individuals (59), reducing incidence by 31%; however, it unfortunately is contraindicated with impaired renal function. There is at this time no long-term outcome data justifying use of the insulin-sensitizing thiazolidinediones in nonhyperglycemic metabolic syndrome. Moreover, the increased adiposity associated with these PPAR- agonists is intuitively concerning despite its putative nonabdominal localization. Although the PPAR- and PPAR- agonists seem superficially ideal, the risk that an increased metabolic rate—especially without concomitant calorie restriction—may reduce life span is not trivial, backed by a large body of literature, including primates (126). What can and should be aggressively addressed in metabolic syndrome at all stages is pharmacologic management of hypertriglyceridemia and low HDL cholesterol. Newer statins are more effective in reducing TG as well as LDL cholesterol, although cost will be the perennial drawback. Fenofibrate (a PPAR- agonist) and niacin are effective tools for hypertriglyceridemia and can each (but not both) be combined with a statin when needed. Management issues in metabolic syndrome have been recently reviewed (45).

In summary, hand in hand with the ongoing epidemic of obesity, the prevalence of obesity-initiated metabolic syndrome—with its increased risk for diabetes, cardiovascular disease, and CKD—has reached alarming proportions. Its impact on renal disease is ensured if only because hypertension and insulin resistance/diabetes are defining components of the syndrome. However, our challenge is to define and ultimately prevent obesity-related renal injury before onset of irreversible damage. Evidence reviewed supports the concept that obesity—via excess body mass and consequently excretory load and/or via sodium retaining forces requiring compensation—co-opts the kidneys to serve those demands, driving nephromegaly and glomerulomegaly, inducing hyperperfusion/hyperfiltration, and creating intraglomerular changes that mimic those of reduced nephron number. In effect, the kidney in obesity has the hemodynamic equivalent of CKD. In addition to the injury susceptibilities that this confers, the systemic signals that mediate metabolic derangement in abdominal obesity are likely to have an impact on renal glomerular and tubular cells: increased FFA, hyperinsulinemia/insulin resistance, reduced adiponectin, and leptin resistance. Identifying functional and structural consequences of these early changes may lead to new renoprotective interventions or dictate earlier initiation of established ones. In the meantime, our growing body of knowledge on optimal renal protection in all stages of CKD seems imminently applicable to even the earliest stages of obesity-initiated metabolic syndrome.

	Acknowledgments

 
Investigative work cited is supported by National Institutes of Health/National Institute of Child Health and Human Development Grants PO1 HD034430 and RO1 HD42570. I gratefully acknowledges the indispensable scientific contributions and administrative leadership of Dr. Kent Thornburg, Professor of Medicine and Physiology/Pharmacology and Director of the OHSU Heart Research Center, in development of the microswine model.

	References

Top Introduction Metabolic Syndrome Defined: A... Prevalence and Cardiovascular... Pathogenesis of Obesity... Generation of Obesity-Associated... Liver Skeletal Muscle Pancreas Vascular Endothelium Role of Leptin Resistance... Meanwhile, Back to Fat Predisposition to Obesity... Lessons from Intrauterine Growth... Genetic Predisposition to... Renal Injury in Obesity... Potential Mechanisms of Early... Excess Excretory Load Adverse Adaptations to Excess... Adverse Renal Effects of... Renal Lipotoxicity? References

 

1. Reaven GM: Role of insulin resistance in human disease. Diabetes 37: 1595–1607, 1988[Abstract]
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143–3421, 2002[Free Full Text]
3. McKeown NM, Meigs JB, Liu S, Saltzman E, Wilson PW, Jacques PF: Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care 27: 538–546, 2004[Abstract/Free Full Text]
4. Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas J, Tousoulis D, Toutouza M, Toutouzas P, Stefanadis C: Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. Am Heart J 147: 106–112, 2004[CrossRef][Medline]
5. Lakka TA, Laaksonen DE, Lakka HM, Mannikko N, Niskanen LK, Rauramaa R, Salonen JT: Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome. Med Sci Sports Exerc 35: 1279–1286, 2003[CrossRef][Medline]
6. Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 106: 171–176, 2000[Medline]
7. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA 287: 356–359, 2002[Abstract/Free Full Text]
8. Hanley AJ, Wagenknecht LE, D’Agostino RB Jr, Zinman B, Haffner SM: Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes 52: 2740–2747, 2003[Abstract/Free Full Text]
9. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288: 1723–1727, 2002[Abstract/Free Full Text]
10. Segura J, Campo C, Roldan C, Christiansen H, Vigil L, Garcia-Robles R, Rodicio JL, Ruilope LM: Hypertensive renal damage in metabolic syndrome is associated with glucose metabolism disturbances. J Am Soc Nephrol 15 [Suppl 1]: S37–S42, 2004
11. Denke MA: Connections between obesity and dyslipidaemia. Curr Opin Lipidol 12: 625–628, 2001[CrossRef][Medline]
12. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna RC, Muggeo M: Metabolic syndrome: Epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord 27: 1283–1289, 2003[CrossRef][Medline]
13. Cruz ML, Goran MI: The metabolic syndrome in children and adolescents. Curr Diab Rep 4: 53–62, 2004[Medline]
14. Cruz ML, Weigensberg MJ, Huang TT, Ball G, Shaibi GQ, Goran MI: The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J Clin Endocrinol Metab 89: 108–113, 2004[Abstract/Free Full Text]
15. Ogden CL, Flegal KM, Carroll MD, Johnson CL: Prevalence and trends in overweight among US children and adolescents, 1999–2000. JAMA 288: 1728–1732, 2002[Abstract/Free Full Text]
16. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA: Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 156: 1070–1077, 2002[Abstract/Free Full Text]
17. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709–2716, 2002[Abstract/Free Full Text]
18. Ninomiya JK, L’Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS: Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. Circulation 109: 42–46, 2004[Abstract/Free Full Text]
19. Unger RH: Minireview: Weapons of lean body mass destruction: The role of ectopic lipids in the metabolic syndrome. Endocrinology 144: 5159–5165, 2003[Abstract/Free Full Text]
20. Unger RH: The physiology of cellular liporegulation. Annu Rev Physiol 65: 333–347, 2003[CrossRef][Medline]
21. Unger RH: Lipid overload and overflow: Metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 14: 398–403, 2003[CrossRef][Medline]
22. McGarry JD: Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51: 7–18, 2002[Free Full Text]
23. Schaffer JE: Lipotoxicity: When tissues overeat. Curr Opin Lipidol 14: 281–287, 2003[CrossRef][Medline]
24. Unger RH, Orci L: Lipoapoptosis: Its mechanism and its diseases. Biochim Biophys Acta 1585: 202–212, 2002[Medline]
25. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I: Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24: 29–33, 2004[Abstract/Free Full Text]
26. Havel PJ: Update on adipocyte hormones: Regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 53 [Suppl 1]: S143–S151, 2004[Abstract/Free Full Text]
27. Havel PJ: Control of energy homeostasis and insulin action by adipocyte hormones: Leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 13: 51–59, 2002[CrossRef][Medline]
28. Cnop M, Landchild MJ, Vidal J, Havel PJ, Knowles NG, Carr DR, Wang F, Hull RL, Boyko EJ, Retzlaff BM, Walden CE, Knopp RH, Kahn SE: The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: Distinct metabolic effects of two fat compartments. Diabetes 51: 1005–1015, 2002[Abstract/Free Full Text]
29. Arch JR, Stock MJ, Trayhurn P: Leptin resistance in obese humans: Does it exist and what does it mean? Int J Obes Relat Metab Disord 22: 1159–1163, 1998[CrossRef][Medline]
30. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821–1830, 2003[CrossRef][Medline]
31. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796–1808, 2003[CrossRef][Medline]
32. Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108: 414–419, 2003[Abstract/Free Full Text]
33. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 259: 87–91, 1993[Abstract/Free Full Text]
34. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB: Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53: 336–346, 2004[Abstract/Free Full Text]
35. Lyon CJ, Hsueh WA: Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 115 [Suppl 8A]: 62S–68S, 2003
36. Fernandez-Real JM, Ricart W: Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24: 278–301, 2003[Abstract/Free Full Text]
37. Oron-Herman M, Rosenthal T, Sela BA: Hyperhomocysteinemia as a component of syndrome X. Metabolism 52: 1491–1495, 2003[CrossRef][Medline]
38. Giacchetti G, Faloia E, Mariniello B, Sardu C, Gatti C, Camilloni MA, Guerrieri M, Mantero F: Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 15: 381–388, 2002[CrossRef][Medline]
39. Poirier P, Despres JP: Waist circumference, visceral obesity, and cardiovascular risk. J Cardiopulm Rehabil 23: 161–169, 2003[CrossRef][Medline]
40. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI: Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103: 253–259, 1999[Medline]
41. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI: Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48: 1270–1274, 1999[Abstract]
42. Thorburn AW, Baldwin ME, Rosella G, Zajac JD, Fabris S, Song S, Proietto J: Features of syndrome X develop in transgenic rats expressing a non-insulin responsive phosphoenolpyruvate carboxykinase gene. Diabetologia 42: 419–426, 1999[CrossRef][Medline]
43. Kim SP, Ellmerer M, Van Citters GW, Bergman RN: Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. Diabetes 52: 2453–2460, 2003[Abstract/Free Full Text]
44. Avramoglu RK, Qiu W, Adeli K: Mechanisms of metabolic dyslipidemia in insulin resistant states: Deregulation of hepatic and intestinal lipoprotein secretion. Front Biosci 8: d464–d476, 2003[Medline]
45. Scott CL: Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol 92: 35i–42i, 2003[CrossRef][Medline]
46. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288–1295, 2002[CrossRef][Medline]
47. Hardie DG: Minireview: The AMP-activated protein kinase cascade: The key sensor of cellular energy status. Endocrinology 144: 5179–5183, 2003[Abstract/Free Full Text]
48. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941–946, 2001[CrossRef][Medline]
49. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI: Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350: 664–671, 2004[Abstract/Free Full Text]
50. Kelley DE, He J, Menshikova EV, Ritov VB: Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51: 2944–2950, 2002[Abstract/Free Full Text]
51. He J, Watkins S, Kelley DE: Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity. Diabetes 50: 817–823, 2001[Abstract/Free Full Text]
52. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI: Mitochondrial dysfunction in the elderly: Possible role in insulin resistance. Science 300: 1140–1142, 2003[Abstract/Free Full Text]
53. Reusch JE, Regensteiner JG, Watson PA: Novel actions of thiazolidinediones on vascular function and exercise capacity. Am J Med 115 [Suppl 8A]: 69S–74S, 2003
54. Wu H, Kanatous SB, Thurmond FA, Gallardo T, Isotani E, Bassel-Duby R, Williams RS: Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science 296: 349–352, 2002[Abstract/Free Full Text]
55. Bodkin NL, Hannah JS, Ortmeyer HK, Hansen BC: Central obesity in rhesus monkeys: Association with hyperinsulinemia, insulin resistance and hypertriglyceridemia? Int J Obes Relat Metab Disord 17: 53–61, 1993[Medline]
56. Krauss S, Zhang CY, Scorrano L, Dalgaard LT, St Pierre J, Grey ST, Lowell BB: Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction. J Clin Invest 112: 1831–1842, 2003[CrossRef][Medline]
57. Brownlee M: A radical explanation for glucose-induced beta cell dysfunction. J Clin Invest 112: 1788–1790, 2003[CrossRef][Medline]
58. Sakai K, Matsumoto K, Nishikawa T, Suefuji M, Nakamaru K, Hirashima Y, Kawashima J, Shirotani T, Ichinose K, Brownlee M, Araki E: Mitochondrial reactive oxygen species reduce insulin secretion by pancreatic beta-cells. Biochem Biophys Res Commun 300: 216–222, 2003[CrossRef][Medline]
59. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393–403, 2002[Abstract/Free Full Text]
60. Montagnani M, Ravichandran LV, Chen H, Esposito DL, Quon MJ: Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol 16: 1931–1942, 2002[Abstract/Free Full Text]
61. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278: 45021–45026, 2003[Abstract/Free Full Text]
62. Lee Y, Wang MY, Kakuma T, Wang ZW, Babcock E, McCorkle K, Higa M, Zhou YT, Unger RH: Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia. J Biol Chem 276: 5629–5635, 2001[Abstract/Free Full Text]
63. Orci L, Cook WS, Ravazzola M, Wang MY, Park BH, Montesano R, Unger RH: Rapid transformation of white adipocytes into fat-oxidizing machines. Proc Natl Acad Sci U S A 101: 2058–2063, 2004[Abstract/Free Full Text]
64. Petersen KF, Shulman GI: Cellular mechanism of insulin resistance in skeletal muscle. J R Soc Med 95 [Suppl 42]: 8–13, 2002
65. Katz JR, Mohamed-Ali V, Wood PJ, Yudkin JS, Coppack SW: An in vivo study of the cortisol-cortisone shuttle in subcutaneous abdominal adipose tissue. Clin Endocrinol (Oxf) 50: 63–68, 1999[CrossRef][Medline]
66. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Heintze U, Janke J, Luft FC, Sharma AM: Regulation of 11beta-HSD genes in human adipose tissue: Influence of central obesity and weight loss. Obes Res 12: 9–17, 2004[Medline]
67. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS: A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166–2170, 2001[Abstract/Free Full Text]
68. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, Flier JS: Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 112: 83–90, 2003[CrossRef][Medline]
69. Seckl JR, Morton NM, Chapman KE, Walker BR: Glucocorticoids and 11-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 59: 359–393, 2004[Abstract/Free Full Text]
70. Rask-Madsen C, Dominguez H, Ihlemann N, Hermann T, Kober L, Torp-Pedersen C: Tumor necrosis factor-alpha inhibits insulin’s stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 108: 1815–1821, 2003[Abstract/Free Full Text]
71. Jaber LA, Brown MB, Hammad A, Zhu Q, Herman WH: The prevalence of the metabolic syndrome among Arab Americans. Diabetes Care 27: 234–238, 2004[Abstract/Free Full Text]
72. Iossa S, Lionetti L, Mollica MP, Crescenzo R, Botta M, Barletta A, Liverini G: Effect of high-fat feeding on metabolic efficiency and mitochondrial oxidative capacity in adult rats. Br J Nutr 90: 953–960, 2003[CrossRef][Medline]
73. Mathews SG, Phillips DI, Challis JR, Cox DB, Thomas EJ, McMillen C, Lye SJ, McDonald RB, Wintour EM, Morrison JL, Sloboda DM: The hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes in early life: Problems and perspectives. In: Fetal Origins of Cardiovascular and Lung Disease, edited by Barker DJ, Lenfant C, New York, Marcel Dekker, 2001, pp 229–240
74. Hoet JJ, Hanson MA: Intrauterine nutrition: Its importance during critical periods for cardiovascular and endocrine development. J Physiol 514: 617–627, 1999[Abstract/Free Full Text]
75. Osmond C, Barker DJ: Fetal, infant, and childhood growth are predictors of coronary heart disease, diabetes, and hypertension in adult men and women. Environ Health Perspect 108 [Suppl 3]: 545–553, 2000[Medline]
76. Phillips DI: Non-insulin-dependent diabetes and obesity. In: Fetal Origins of Cardiovascular and Lung Disease, edited by Barker DJ, Lenfant C, New York, Marcel Dekker, 2001, pp 141–159
77. al Ghazali W, Chita SK, Chapman MG, Allan LD: Evidence of redistribution of cardiac output in asymmetrical growth retardation. Br J Obstet Gynaecol 96: 697–704, 1989[Medline]
78. Hinchliffe SA, Lynch MR, Sargent PH, Howard CV, van Velzen D: The effect of intrauterine growth retardation on the development of renal nephrons. Br J Obstet Gynaecol 99: 296–301, 1992[Medline]
79. Forsen T, Eriksson JG, Tuomilehto J, Osmond C, Barker DJ: Growth in utero and during childhood among women who develop coronary heart disease: Longitudinal study. BMJ 319: 1403–1407, 1999[Abstract/Free Full Text]
80. Eriksson JG, Forsen T, Tuomilehto J, Winter PD, Osmond C, Barker DJ: Catch-up growth in childhood and death from coronary heart disease: Longitudinal study. BMJ 318: 427–431, 1999[Abstract/Free Full Text]
81. Vickers MH, Breier BH, Cutfield WS, Hofman PL, Gluckman PD: Fetal origins of hyperphagia, obesity, and hypertension and postnatal amplification by hypercaloric nutrition. Am J Physiol Endocrinol Metab 279: E83–E87, 2000[Abstract/Free Full Text]
82. Ong KK, Ahmed ML, Emmett PM, Preece MA, Dunger DB: Association between postnatal catch-up growth and obesity in childhood: Prospective cohort study. BMJ 320: 967–971, 2000[Abstract/Free Full Text]
83. Valdez R, Athens MA, Thompson GH, Bradshaw BS, Stern MP: Birthweight and adult health outcomes in a biethnic population in the USA. Diabetologia 37: 624–631, 1994[Medline]
84. Bhargava SK, Sachdev HS, Fall CH, Osmond C, Lakshmy R, Barker DJ, Biswas SK, Ramji S, Prabhakaran D, Reddy KS: Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med 350: 865–875, 2004[Abstract/Free Full Text]
85. Eriksson JG, Forsen T, Tuomilehto J, Osmond C, Barker DJ: Early adiposity rebound in childhood and risk of type 2 diabetes in adult life. Diabetologia 46: 190–194, 2003[Medline]
86. Eriksson JG, Forsen TJ, Osmond C, Barker DJ: Pathways of infant and childhood growth that lead to type 2 diabetes. Diabetes Care 26: 3006–3010, 2003[Abstract/Free Full Text]
87. Barker DJ, Forsen T, Eriksson JG, Osmond C: Growth and living conditions in childhood and hypertension in adult life: A longitudinal study. J Hypertens 20: 1951–1956, 2002[CrossRef][Medline]
88. Eriksson J, Forsen T, Tuomilehto J, Osmond C, Barker D: Fetal and childhood growth and hypertension in adult life. Hypertension 36: 790–794, 2000[Abstract/Free Full Text]
89. Crowther NJ, Cameron N, Trusler J, Gray IP: Association between poor glucose tolerance and rapid post natal weight gain in seven-year-old children. Diabetologia 41: 1163–1167, 1998[CrossRef][Medline]
90. Yajnik CS, Fall CH, Coyaji KJ, Hirve SS, Rao S, Barker DJ, Joglekar C, Kellingray S: Neonatal anthropometry: The thin-fat Indian baby. The Pune Maternal Nutrition Study. Int J Obes Relat Metab Disord 27: 173–180, 2003[CrossRef][Medline]
91. Hales CN: Fetal and infant growth and impaired glucose tolerance in adulthood: The "thrifty phenotype" hypothesis revisited. Acta Paediatr Suppl 422: 73–77, 1997[Medline]
92. Brenner BM, Chertow GM: Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis 23: 171–175, 1994[Medline]
93. Woods LL, Rasch R: Perinatal ANG II programs adult blood pressure, glomerular number, and renal function in rats. Am J Physiol 275: R1593–R1599, 1998
94. Woods LL, Ingelfinger JR, Nyengaard JR, Rasch R: Maternal protein restriction suppresses the newborn renin-angiotensin system and programs adult hypertension in rats. Pediatr Res 49: 460–467, 2001[Medline]
95. Vehaskari VM, Aviles DH, Manning J: Prenatal programming of adult hypertension in the rat. Kidney Int 59: 238–245, 2001[Medline]
96. Petrik J, Reusens B, Arany E, Remacle C, Coelho C, Hoet JJ, Hill DJ: A low protein diet alters the balance of islet cell replication and apoptosis in the fetal and neonatal rat and is associated with a reduced pancreatic expression of insulin-like growth factor-II. Endocrinology 140: 4861–4873, 1999[Abstract/Free Full Text]
97. Garofano A, Czernichow P, Breant B: Beta-cell mass and proliferation following late fetal and early postnatal malnutrition in the rat. Diabetologia 41: 1114–1120, 1998[CrossRef][Medline]
98. Holemans K, Aerts L, van Assche FA: Lifetime consequences of abnormal fetal pancreatic development. J Physiol 547: 11–20, 2003[Abstract/Free Full Text]
99. Wigmore PM, Stickland NC: Muscle development in large and small pig fetuses. J Anat 137: 235–245, 1983
100. Dwyer CM, Madgwick AJ, Ward SS, Stickland NC: Effect of maternal undernutrition in early gestation on the development of fetal myofibres in the guinea-pig. Reprod Fertil Dev 7: 1285–1292, 1995[CrossRef][Medline]
101. Park KS, Kim SK, Kim MS, Cho EY, Lee JH, Lee KU, Pak YK, Lee HK: Fetal and early postnatal protein malnutrition cause long-term changes in rat liver and muscle mitochondria. J Nutr 133: 3085–3090, 2003[Abstract/Free Full Text]
102. Yajnik CS: Fetal origins of insulin resistance and type 2 diabetes in India. [Abstract]. Pediatr Res 53: 7A, 2003
103. Lackland DT, Bendall HE, Osmond C, Egan BM, Barker DJ: Low birth weights contribute to high rates of early-onset chronic renal failure in the Southeastern United States. Arch Intern Med 160: 1472–1476, 2000[Abstract/Free Full Text]
104. Bagby SP, Ogden B, LeBard L, Woods L, Corless C, Luo Z: Maternal protein restriction during nephrogenesis in microswine causes asymmetric intrauterine growth retardation in neonates and hypertension with body weight excess in adults. [Abstract]. J Am Soc Nephrol 12: 461A, 2001
105. McNeill J, Speth R, McPherson EA, Dirkx T, Saunders K, Bagby S: Circulating renin/AngII components in neonatal and adult microswine offspring of maternal protein restriction [Abstract]. FASEB J 18: A687, 2004
106. Bagby S, Luo Z, Speth R, McPherson EA, Xue H, Roullet JB: Hypertensive adult offspring of 1% maternal protein restriction in microswine show increased intrarenal AngII and selective renal vascular hyperreactivity to AngII [Abstract]. J Am Soc Nephrol 13: 329A, 2002
107. Carey RM, Soragy HM: The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 14: 274–281, 2003[CrossRef][Medline]
108. van Assche FA, Holemans K, Aerts L: Long-term consequences for offspring of diabetes during pregnancy. Br Med Bull 60: 173–182, 2001[Abstract/Free Full Text]
109. Levitt NS, Lindsay RS, Holmes MC, Seckl JR: Dexamethasone in the last week of pregnancy attenuates hippocampal glucocorticoid receptor gene expression and elevates blood pressure in the adult offspring in the rat. Neuroendocrinology 64: 412–418, 1996[Medline]
110. Srinivasan M, Laychock SG, Hill DJ, Patel MS: Neonatal nutrition: Metabolic programming of pancreatic islets and obesity. Exp Biol Med (Maywood) 228: 15–23, 2003[Abstract/Free Full Text]
111. Stewart RJ, Preece RF, Sheppard HG: Recovery from long-term protein-energy deficiency. Proc Nutr Soc 32: 103A, 1973
112. Stein AD, Lumey LH: The relationship between maternal and offspring birth weights after maternal prenatal famine exposure: The Dutch Famine Birth Cohort Study. Hum Biol 72: 641–654, 2000[Medline]
113. Tremblay A, Bouchard L, Bouchard C, Despres JP, Drapeau V, Perusse L: Long-term adiposity changes are related to a glucocorticoid receptor polymorphism in young females. J Clin Endocrinol Metab 88: 3141–3145, 2003[Abstract/Free Full Text]
114. Buemann B, Vohl MC, Chagnon M, Chagnon YC, Gagnon J, Perusse L, Dionne F, Despres JP, Tremblay A, Nadeau A, Bouchard C: Abdominal visceral fat is associated with a BclI restriction fragment length polymorphism at the glucocorticoid receptor gene locus. Obes Res 5: 186–192, 1997[Medline]
115. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, Froguel P, Kimura S, Nagai R, Kadowaki T: Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278: 40352–40363, 2003[Abstract/Free Full Text]
116. Muller YL, Bogardus C, Pedersen O, Baier L: A Gly482Ser missense mutation in the peroxisome proliferator-activated receptor gamma coactivator-1 is associated with altered lipid oxidation and early insulin secretion in Pima Indians. Diabetes 52: 895–898, 2003[Abstract/Free Full Text]
117. Muller YL, Bogardus C, Beamer BA, Shuldiner AR, Baier LJ: A functional variant in the peroxisome proliferator-activated receptor 2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. Diabetes 52: 1864–1871, 2003[Abstract/Free Full Text]
118. Eriksson J, Lindi V, Uusitupa M, Forsen T, Laakso M, Osmond C, Barker D: The effects of the Pro12Ala polymorphism of the PPAR-2 gene on lipid metabolism interact with body size at birth. Clin Genet 64: 366–370, 2003[CrossRef][Medline]
119. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51: 1908–1919, 1997[Medline]
120. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ: Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communities study. Kidney Int 58: 293–301, 2000[CrossRef][Medline]
121. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J: The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140: 167–174, 2004[Abstract/Free Full Text]
122. Palaniappan L, Carnethon M, Fortmann SP: Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 16: 952–958, 2003[CrossRef][Medline]
123. Chen J, Muntner P, Hamm LL, Fonseca V, Batuman V, Whelton PK, He J: Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 14: 469–477, 2003[Abstract/Free Full Text]
124. Cusumano AM, Bodkin NL, Hansen BC, Iotti R, Owens J, Klotman PE, Kopp JB: Glomerular hypertrophy is associated with hyperinsulinemia and precedes overt diabetes in aging rhesus monkeys. Am J Kidney Dis 40: 1075–1085, 2002[CrossRef][Medline]
125. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE: Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 12: 1211–1217, 2001[Abstract/Free Full Text]
126. Bodkin NL, Alexander TM, Ortmeyer HK, Johnson E, Hansen BC: Mortality and morbidity in laboratory-maintained Rhesus monkeys and effects of long-term dietary restriction. J Gerontol A Biol Sci Med Sci 58: 212–219, 2003
127. Hall JE, Henegar JR, Dwyer TM, Liu J, da Silva AA, Kuo JJ, Tallam L: Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther 11: 41–54, 2004[CrossRef][Medline]
128. Adelman RD: Obesity and renal disease. Curr Opin Nephrol Hypertens 11: 331–335, 2002[CrossRef][Medline]
129. Praga M: Obesity—A neglected culprit in renal disease. Nephrol Dial Transplant 17: 1157–1159, 2002[Free Full Text]
130. Colman RJ, Roecker EB, Ramsey JJ, Kemnitz JW: The effect of dietary restriction on body composition in adult male and female rhesus macaques. Aging (Milano) 10: 83–92, 1998[Medline]
131. Verani RR: Obesity-associated focal segmental glomerulosclerosis: Pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kidney Dis 20: 629–634, 1992[Medline]
132. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U: Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 278: F817–F822, 2000[Abstract/Free Full Text]
133. Morales E, Vlaero A, Leon M, Hernandez E, Praga M: Benefical effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 41: 319–327, 2003[CrossRef][Medline]
134. Adelman RD, Restaino IG, Alon US, Blowey DL: Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents. J Pediatr 138: 481–485, 2001[CrossRef][Medline]
135. Praga M, Hernandez E, Herrero JC, Morales E, Revilla Y, Diaz-Gonzalez D, Rodicio JL: Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 58: 2111–2118, 2000[CrossRef][Medline]
136. Schwimmer JA, Markowitz GS, Valeri AM, Imbriano LJ, Alvis R, D’Agati VD: Secondary focal segmental glomerulosclerosis in non-obese patients with increased muscle mass. Clin Nephrol 60: 233–241, 2003[Medline]
137. Thomson SC, Vallon V, Blantz RC: Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol 286: F8–F15, 2004[Abstract/Free Full Text]
138. Abrass CK, Raugi GJ, Gabourel LS, Lovett DH: Insulin and insulin-like growth factor I binding to cultured rat glomerular mesangial cells. Endocrinology 123: 2432–2439, 1988[Abstract/Free Full Text]
139. Pete G, Walsh M, Hu Y, Sowers J, Dunbar JC: Insulin-like growth factor-I decreases mean blood pressure and selectively increases regional blood flow in normal rats. Proc Soc Exp Biol Med 213: 187–192, 1996[CrossRef][Medline]
140. Hirschberg R, Adler S: Insulin-like growth factor system and the kidney: Physiology, pathophysiology, and therapeutic implications. Am J Kidney Dis 31: 901–919, 1998[Medline]
141. Kreisberg JI: Insulin requirement for contraction of cultured rat glomerular mesangial cells in response to angiotensin II: Possible role for insulin in modulating glomerular hemodynamics. Proc Natl Acad Sci U S A 79: 4190–4192, 1982[Abstract/Free Full Text]
142. Abrass CK, Spicer D, Raugi GJ: Insulin induces a change in extracellular matrix glycoproteins synthesized by rat mesangial cells in culture. Kidney Int 46: 613–620, 1994[Medline]
143. Abrass CK, Peterson CV, Raugi GJ: Phenotypic expression of collagen types in mesangial matrix of diabetic and nondiabetic rats. Diabetes 37: 1695–1702, 1988[Abstract]
144. Abrass CK, Spicer D, Raugi GJ: Induction of nodular sclerosis by insulin in rat mesangial cells in vitro: Studies of collagen. Kidney Int 47: 25–37, 1995[Medline]
145. Huang Z, Bodkin NL, Ortmeyer HK, Hansen BC, Shuldiner AR: Hyperinsulinemia is associated with altered insulin receptor mRNA splicing in muscle of the spontaneously obese diabetic rhesus monkey. J Clin Invest 94: 1289–1296, 1994
146. Thomas ME, Schreiner GF: Contribution of proteinuria to progressive renal injury: Consequences of tubular uptake of fatty acid bearing albumin. Am J Nephrol 13: 385–398, 1993[Medline]
147. Kamijo A, Kimura K, Sugaya T, Mayamouchi M, Hase H, Kaneko T, Hirata Y, Goto A, Fujita T, Omata M: Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int 62: 1628–1637, 2002[CrossRef][Medline]
148. Mulyadi L, Stevens C, Munro S, Lingard J, Bermingham M: Body fat distribution and total body fat as risk factors for microalbuminuria in the obese. Ann Nutr Metab 45: 67–71, 2001[Medline]
149. Weisginer JR, Kempson RL, Eldridge FL, Swenson RS: The nephrotic syndrome: A complication of massive obesity. Ann Intern Med 81: 440–447, 1974
150. Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD: Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 59: 1498–1509, 2001[CrossRef][Medline]
151. Praga M, Hernandez E, Morales E, Campos AP, Valero MA, Martinez MA, Leon M: Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 16: 1790–1798, 2001[Abstract/Free Full Text]
152. Hansen BC, Bodkin NL, Ortmeyer HK: Calorie restriction in nonhuman primates: Mechanisms of reduced morbidity and mortality. Toxicol Sci 52: 56–60, 1999[Abstract/Free Full Text]
153. Lane MA, Ingram DK, Roth GS: Calorie restriction in nonhuman primates: Effects on diabetes and cardiovascular disease risk. Toxicol Sci 52: 41–48, 1999[Abstract/Free Full Text]
154. Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, Uusitupa M, Tuomilehto J: The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 26: 3230–3236, 2003[Abstract/Free Full Text]
155. Abrass CK, Berfield AK: Phenotypic modulation of rat glomerular visceral epithelial cells by culture substratum. J Am Soc Nephrol 5: 1591–1599, 1995[Abstract]
156. Sharma AM: Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 44: 12–19, 2004[Abstract/Free Full Text]

This article has been cited by other articles:

				S. Chung, C. W. Park, S. J. Shin, J. H. Lim, H. W. Chung, D.-Y. Youn, H. W. Kim, B. S. Kim, J.-H. Lee, G.-H. Kim, et al. Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats Nephrol. Dial. Transplant., February 1, 2010; 25(2): 389 - 399. [Abstract] [Full Text] [PDF]

				D. S. Goumenos, B. Kawar, M. El Nahas, S. Conti, B. Wagner, C. Spyropoulos, J. G. Vlachojannis, A. Benigni, and F. Kalfarentzos Early histological changes in the kidney of people with morbid obesity Nephrol. Dial. Transplant., December 1, 2009; 24(12): 3732 - 3738. [Abstract] [Full Text] [PDF]

				X. X. Wang, T. Jiang, Y. Shen, L. Adorini, M. Pruzanski, F. J. Gonzalez, P. Scherzer, L. Lewis, S. Miyazaki-Anzai, and M. Levi The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria Am J Physiol Renal Physiol, December 1, 2009; 297(6): F1587 - F1596. [Abstract] [Full Text] [PDF]

				F. Afshinnia, T. J. Wilt, S. Duval, A. Esmaeili, and H. N. Ibrahim Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts Nephrol. Dial. Transplant., November 27, 2009; (2009) gfp640v1. [Abstract] [Full Text] [PDF]

				I. A. Bobulescu, M. Dubree, J. Zhang, P. McLeroy, and O. W. Moe Reduction of renal triglyceride accumulation: effects on proximal tubule Na+/H+ exchange and urinary acidification Am J Physiol Renal Physiol, November 1, 2009; 297(5): F1419 - F1426. [Abstract] [Full Text] [PDF]

				K. F. Adams, M. F. Leitzmann, D. Albanes, V. Kipnis, S. C. Moore, A. Schatzkin, and W.-H. Chow Body Size and Renal Cell Cancer Incidence in a Large US Cohort Study Am. J. Epidemiol., August 1, 2008; 168(3): 268 - 277. [Abstract] [Full Text] [PDF]

				I. A. Bobulescu, M. Dubree, J. Zhang, P. McLeroy, and O. W. Moe Effect of renal lipid accumulation on proximal tubule Na+/H+ exchange and ammonium secretion Am J Physiol Renal Physiol, June 1, 2008; 294(6): F1315 - F1322. [Abstract] [Full Text] [PDF]

				L. G. Sanchez-Lozada, E. Tapia, P. Bautista-Garcia, V. Soto, C. Avila-Casado, I. P. Vega-Campos, T. Nakagawa, L. Zhao, M. Franco, and R. J. Johnson Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome Am J Physiol Renal Physiol, April 1, 2008; 294(4): F710 - F718. [Abstract] [Full Text] [PDF]

				K. A. Griffin, H. Kramer, and A. K. Bidani Adverse renal consequences of obesity Am J Physiol Renal Physiol, April 1, 2008; 294(4): F685 - F696. [Abstract] [Full Text] [PDF]

				P. Korantzopoulos, M. Elisaf, and H. J. Milionis Multifactorial intervention in metabolic syndrome targeting at prevention of chronic kidney disease ready for prime time? Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2768 - 2774. [Full Text] [PDF]

				S. Kume, T. Uzu, S.-i. Araki, T. Sugimoto, K. Isshiki, M. Chin-Kanasaki, M. Sakaguchi, N. Kubota, Y. Terauchi, T. Kadowaki, et al. Role of Altered Renal Lipid Metabolism in the Development of Renal Injury Induced by a High-Fat Diet J. Am. Soc. Nephrol., October 1, 2007; 18(10): 2715 - 2723. [Abstract] [Full Text] [PDF]

				I. M. Wahba and R. H. Mak Obesity and Obesity-Initiated Metabolic Syndrome: Mechanistic Links to Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 550 - 562. [Abstract] [Full Text] [PDF]

				V. G. Athyros, D. P. Mikhailidis, E. N. Liberopoulos, A. I. Kakafika, A. Karagiannis, A. A. Papageorgiou, K. Tziomalos, E. S. Ganotakis, and M. Elisaf Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study Nephrol. Dial. Transplant., January 1, 2007; 22(1): 118 - 127. [Abstract] [Full Text] [PDF]

				A. A. Eddy and A. B. Fogo Plasminogen Activator Inhibitor-1 in Chronic Kidney Disease: Evidence and Mechanisms of Action J. Am. Soc. Nephrol., November 1, 2006; 17(11): 2999 - 3012. [Full Text] [PDF]

				T. Jiang, Z. Wang, G. Proctor, S. Moskowitz, S. E. Liebman, T. Rogers, M. S. Lucia, J. Li, and M. Levi Diet-induced Obesity in C57BL/6J Mice Causes Increased Renal Lipid Accumulation and Glomerulosclerosis via a Sterol Regulatory Element-binding Protein-1c-dependent Pathway J. Biol. Chem., September 16, 2005; 280(37): 32317 - 32325. [Abstract] [Full Text] [PDF]

				D. J.P. Barker and S. P. Bagby Developmental Antecedents of Cardiovascular Disease: A Historical Perspective J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2537 - 2544. [Abstract] [Full Text] [PDF]

				R. J. Johnson, M. S. Segal, T. Srinivas, A. Ejaz, W. Mu, C. Roncal, L. G. Sanchez-Lozada, M. Gersch, B. Rodriguez-Iturbe, D.-H. Kang, et al. Essential Hypertension, Progressive Renal Disease, and Uric Acid: A Pathogenetic Link? J. Am. Soc. Nephrol., July 1, 2005; 16(7): 1909 - 1919. [Abstract] [Full Text] [PDF]

				M. Kurella, J. C. Lo, and G. M. Chertow Metabolic Syndrome and the Risk for Chronic Kidney Disease among Nondiabetic Adults J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2134 - 2140. [Abstract] [Full Text] [PDF]

				F. Togel, Z. Hu, K. Weiss, J. Isaac, C. Lange, C. Westenfelder, T. Stasko, M.D. Brown, J.A. Carucci, S. Euvrard, et al. Amelioration of Acute Renal Failure by Stem Cell Therapy--Paracrine Secretion Versus Transdifferentiation into Resident Cells: Administered Mesenchymal Stem Cells Protect against Ischemic Acute Renal Failure through Differentiation-Independent Mechanisms. Am J Physiol Renal Physiol E-pub February 15, 2005 J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1153 - 1163. [Full Text] [PDF]

				T. Lau, P.-O. Carlsson, P.S. Leung, C. Wolfrum, E. Asilmaz, E. Luca, J.M. Friedman, M. Stoffel, J.C. Verhave, H.L. Hillege, et al. Why Less Diabetes with Blockade of the Renin-Angiotensin System?: Evidence for a Local Angiotensin-Generating System and Dose-Dependent Inhibition of Glucose-Stimulated Insulin Release by Angiotensin II in Isolated Pancreatic Islets. Diabetologia 47: 240-248, 2004 J. Am. Soc. Nephrol., March 1, 2005; 16(3): 567 - 573. [Full Text] [PDF]

				C. K. Abrass Overview: Obesity: What Does It Have to Do with Kidney Disease? J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2768 - 2772. [Full Text] [PDF]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bagby, S. P. Search for Related Content PubMed PubMed Citation Articles by Bagby, S. P.